Japanese encephalitis virus (JEV) is a positive-stranded enveloped RNA virus that belongs to the family Flaviviridae. Genomic JEV RNA is approximately 11 kb long and encodes 10 proteins, 3 structural and 7 nonstructural. A fIl-length cDNA copy of the JEV genome was constructed by in vitro ligation of two cDNA fragments which encode the 5' (nucleotide positions 1 to 5576) and 3' (nucleotide positions 5577 to 10976) halves of the genome. T7 RNA polymerase transcripts of the ligated full-length cDNA template were infectious when transfected into BHK-21 cells. To identify the recombinant virus, a silent mutation was introduced into the clone encoding the 3' half of the genome, which abolished an XbaI site at nucleotide position 9131. Virus recovered by transfection with the transcripts contained this silent mutation, confirming its identity. Recombinant and parent viruses were identical with respect to growth and plaque production in BHK-21 cells, envelope protein expression in C6/36 cells, and neurovirulence and immunogenicity in mice. Repeated attempts to obtain infectious RNA by transcription from full-length JEV genome cDNA templates cloned into plasmid vectors were unsuccessful. Synthesis of infectious JEV RNA from in vitro-ligated JEV cDNA templates will be useful for molecular and genetic studies of flavivirus replication and virulence.
envelope protein expression in C6/36 cells, and neurovirulence and immunogenicity in mice. Repeated attempts to obtain infectious RNA by transcription from full-length JEV genome cDNA templates cloned into plasmid vectors were unsuccessful. Synthesis of infectious JEV RNA from in vitro-ligated JEV cDNA templates will be useful for molecular and genetic studies of flavivirus replication and virulence.
Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus, found primarily in southeast Asia and the Pacific archipelagos, that causes severe encephalitic and neurologic disease manifestations (4) . During epidemic periods, fatality rates as high as 20% have been noted, particularly among the immunologically naive and those at the extremes of the age spectrum. Hoke et al. (14) reported that the incidence of JEV has approached 16% during some epidemics in Asia, which approaches the incidence observed during poliomyelitis outbreaks in the United States during the 1950s. For these reasons, the development of safe and potent JEV vaccines for human use and understanding of the molecular genetics of virulence are World Health Organization vaccine development priorities (3) .
Sequence analysis of the genomic RNAs of several flaviviruses has revealed that they are organized similarly (31) . Genomes of the virulent JEV strains JaOArS982 (33) , Nakayama (23), Beijing (13) , and SA-14 (24) and of the attenuated vaccine strain SA-1414-2 (24) have been cloned and sequenced, and the genomes have been analyzed at the molecular level. On the basis of nucleotide sequence analysis, JEV strains can be divided into three different groups representing viruses from northern Thailand and Cambodia; southern Thailand, Malaysia, and Indonesia; and Japan, China, Taiwan, the Philippines, and the Indian subcontinent (6) . Antigenic variation has been reported by using both polyclonal (12, 25, 26) and monoclonal antibodies (MAb) to the E protein as assayed by reactivity in the enzyme-linked immunosorbent assay and in complement fixation and neutralization tests (16, 17) .
The JEV genome is a single-stranded RNA molecule, approximately 11 kb in length, of positive sense coding for three structural proteins designated capsid (C), membrane (M), and envelope (E) and seven nonstructural proteins * Corresponding author. designated NS1 through NS5 (13, 24, 33) . The genome is translated into a polyprotein from which structural and nonstructural proteins are processed by cellular (1, 32) and viral proteases (5, 28, 36) . The biological functions and antigenic structure of the flavivirus E protein have been extensively studied; however, the processes of virion morphogenesis, encapsidation of the genomic RNA with C protein, and biological activities of the nonstructural proteins remain largely unknown. Nonstructural protein NS3 is a virus-encoded trypsinlike serine proteinase involved in cleavage of NS2B, NS3, NS4A, and probably NS5 during morphogenesis in the rough endoplasmic reticulum (7, 28, 36) . Subcellular fractions rich in flavivirus RNA polymerase activity are enriched in NS5 and NS3, which are thought to be components of the RNA polymerase (7, 10, 37) . Although biochemical analyses of flavivirus protein function have elucidated some features of their biological importance, the relationship of these functions to virus virulence and disease is poorly understood.
Detailed sequence comparisons between the virulent and attenuated flaviviruses yellow fever virus (YFV) (11), dengue virus (2) , and JEV (24) have implicated specific genomic regions as major determinants of virulence; however, there are numerous nucleotide differences in the sequences which are obviously unrelated to biological function (2, 11, 20, 21, 24) . Assignment of particular mutations to specific phenotypes has been possible through construction of full-length cDNA clones from which infectious progeny virus can be produced (8, 15, 19, 27, 30 Construction of cDNA clones. DNA manipulations were done as previously described (33) . For cDNA synthesis, 3'-end and 5'-end oligonucleotide primers were prepared whose sequence is based on the nucleotide sequence of JEV strain JaOArS982 (33) . The 3'-end primer contained a KpnI site and 25 nucleotides of the negative-sense 3'-terminal region of the JEV genomic RNA. The 5'-end primer contained a Sall site, a T7 RNA polymerase promoter sequence, and 25 nucleotides of the positive-sense 5'-terminal region of the JEV genomic RNA. Genomic RNA and the 3'-end primer were used for first-strand synthesis, using reverse transcriptase (Seikagaku America, Inc., Rockville, Md.). First-strand cDNA and the 5'-end primer were used for second-strand cDNA synthesis, using T4 DNA polymerase and T4 gene 32 product. After synthesis, the cDNA was cut with BamHI and Sall, and the digested cDNAs were inserted into the BamHI and SalI sites of pBR322 and used to transform competent E. coli HB101. JEV cDNA clones pM343 and pH756 were obtained from this cDNA library. The PvuII-SalI fragment, which begins at nucleotide 8782 and extends to the 3' end of the genomic cDNA, was cut from the 3'-half clone pH756 and subcloned into pUC119 (35) . This clone was modified by oligonucleotide site-directed mutagenesis (Amersham Corp., Arlington, Heights, Ill.) to remove the XbaI site at nucleotide 9131 and to introduce an XbaI site at the end of the JEV sequence. The SstII-SalI fragment, extending from nucleotide 8967 to the 3' end of the genomic cDNA, in clone pH756 was replaced with the mutagenized fragment to generate cDNA clone pH756X.
Construction of full-length cDNA template for in vitro RNA transcription. To construct by in vitro ligation the full-length DNA copy of JEV genomic RNA designated IC37, the 5'-half clone pM343 which contained the T7 RNA promoter ( Fig. 1A and 2A ) and JEV sequence from positions 1 to 5576 was digested with Sall and BamHI. The DNA fragment M343 was purified by gel electrophoresis and quantitated, and its purity was verified by gel electrophoresis. To prepare cDNA containing the sequence of the 3' half of the JEV genome, pH756 DNA was digested with BamHI and KpnI (Fig. 1A) ; the cDNA fragment of 5,400 bp which contained cDNA from JEV position 5577 to the end of the genome with an additional C residue ( Fig. 2B ) was purified by agarose gel electrophoresis and quantitated, and its purity was verified by agarose gel electrophoresis. To ligate the 3' and 5' clones together, 3 ,ug of purified M343 fragment and 10 ,ug of H756 DNA fragment were placed in a 100-pI ligation reaction overnight at 4°C. The ligation products were digested with KpnI for 60 min at 37°C; then they were digested with proteinase K (100 pg/ml)-0.2% sodium dodecyl sulfate for 30 min at 37°C. The mixture was then extracted twice with phenol-chloroform and precipitated with ethanol.
A full-length cDNA template of the JEV genome which would transcribe into RNA having the actual terminal sequence of JEV genomic RNA was also prepared. The 3' cDNA clone H756X was cut with BamHI and XbaI, and the DNA fragment (nucleotide positions 5577 to 10976 plus an additional four-nucleotide GATC sequence; Fig. 2C ) was purified by agarose gel electrophoresis. The fragment designated H765X was ligated to purified M343 DNA as before, and the ligation products were digested with XbaI to facilitate synthesis of full-length viral RNA and treated with mung bean nuclease to remove the four extra bases which are part of the XbaI restriction site. The full-length cDNA was then used as a template for JEV RNA transcription.
In vitro RNA transcription. T7 RNA polymerase was purified from E. coli BL21 transformed with clone pAR1219 which contained the T7 RNA polymerase gene (34) . The RNA polymerase was purified from the cells as described previously (9) . For (Fig. 2B) . The cDNA derived from ligation of clone M343 and H756X to produce clone IC37X was cut with XbaI and treated with mung bean nuclease to obtain a template for RNA runoff products (Fig.   2C ). RNA transcripts derived from IC37 were examined by electrophoresis on formaldehyde-denatured 0.8% agarose gels (Fig. 1B) . Full-length transcripts and viral genomic RNA migrated at the same position. Half-length transcripts observed on the gels were thought to be transcribed from the unligated 5'-half cDNA fragment M343 which contained the T7 promoter (Fig. 1A and 2A) . The amount of half-sized RNA transcripts obtained in synthesis reactions was reduced by increasing the molar ratio of the 3'-half cDNA fragment H756 to three times more than that of the 5'-half cDNA fragment in the ligation reaction. Approximately 5 p,g of full-length transcribed RNA was obtained from 0.2 ,g of ligated cDNA template in a 50-,1 T7 RNA polymerase reaction mixture.
As shown in Fig. 2A , T7 RNA polymerase was expected to initiate transcription at the 5'-terminal A residue of the JEV cDNA. Full-length runoff RNA products derived from IC37X should therefore have the same 5' and 3' ends as authentic JEV genomic RNA (Fig. 2C) Fig. 4 , cDNAs of 1,041 bp, representing the PCR-amplified fragment, were observed by agarose gel as expected. When these cDNAs were digested with XbaI, cDNAs from parent and recombinant IC37 viruses were cleaved into 660-and 381-bp fragments; however, cDNA from recombinant IC37X virus was not digested. These results confirmed the identity of recombinant IC37X viral genomic RNA, which retained the point mutation introduced into the cDNA.
Growth rates of parent, IC37, and IC37X viruses were compared in BHK-21 cells infected at multiplicities of 0.01 and 0.1 PFU per cell (Fig. 5 ). There were no significant differences in growth rates among viruses in BHK-21 cells infected at either multiplicity. The maximum virus yield for parent, recombinant IC37, and recombinant IC37X viruses in BHK-21 cells was about 108 PFU/ml after 4 days of incubation. The expression of JEV E protein in cells infected with parent or IC37 virus was examined by using J93 MAb, which reacts only with JEV E protein and with no other fiavivirus antigen. The cytoplasm of cells infected with either parent or IC37 virus was uniformly stained with antibody ( Fig. 6B and D) , confirming the expression and antigenic identity of the viruses. Uninfected cells were not stained (Fig. 6F) .
Neurovirulence and neutralizing antibody production in mice. To compare neurovirulence of parent and recombinant IC37 viruses, 3-week-old Swiss ICR male mice were inoculated with these JEVs by the IP/IC route. As shown in Fig.  7 
